


## Tipiracil hydrochloride

Cat. No.:	HY-A0063
CAS No.:	183204-72-0
Molecular Formula:	C <sub>9</sub> H <sub>12</sub> Cl <sub>2</sub> N <sub>4</sub> O <sub>2</sub>
Molecular Weight:	279.12
Target:	Nucleoside Antimetabolite/Analog
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (179.13 mM; Need ultrasonic)  
 DMSO : < 1 mg/mL (insoluble or slightly soluble)  
 DMF : < 1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	5 mM	10 mM	
	1 mM	3.5827 mL	17.9134 mL	35.8269 mL	
	5 mM	0.7165 mL	3.5827 mL	7.1654 mL	
	10 mM	0.3583 mL	1.7913 mL	3.5827 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Tipiracil (hydrochloride) is a thymidine phosphorylase inhibitor (TPI), used for cancer research.

#### In Vitro

Tipiracil has antiangiogenic effect, and inhibits proliferation of endothelial cells<sup>[1]</sup>.  
 Tipiracil is a potent inhibitor of thymidine phosphorylase, which is the enzyme that degrades FTD<sup>[2]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Biomed Pharmacother. 2021 May 6;139:111672.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- Oncol Rep. 2023 Mar;49(3):52.

- 
- Mod Rheumatol. 2018 May;28(3):495-505.
  - Patent. US Patent 11110111.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Peters GJ, et al. TAS-102: more than an antimetabolite. Lancet Oncol. 2012 Dec;13(12):e518-9.

[2]. Yoshino T, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012 Oct;13(10):993-1001.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA